Chemomab Therapeutics Ltd. announced that on May 31, 2022, Joel Maryles, a member of the Board of Directors of the Company, notified the Company that he will not stand for re-election at the Company's 2022 Annual General Meeting of shareholders, to be held on June 7, 2022, and, accordingly, Maryles' term as a Class I director will expire at the 2022 Annual General Meeting. Maryles' departure is not due to any disagreement between him and the Company, its management, Board or any committee thereof, or any matter relating to the Company's operations, policies or practices.